Is Oruka Therapeutics, Inc. (ORKA) a Buy, Sell, or Hold?
Oruka Therapeutics, Inc.
NASDAQ:ORKA
$87.47 USD
$2.91 (3.44%)
- Volume
- 900.32K
- Average Volume
- 1.82M
- Market Capitalization
- $3.28B
- P/E Ratio
- -36.60
- Dividend Yield
- 0.00%
- Price Target
- $155.50
- Year High
- $97.78
- Year Low
- $12.84
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $23.76
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Lawrence Otto Klein |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ORKA |
| CUSIP | 687604108 |
| CIK | 0000907654 |
| Web | http://www.orukatx.com |
| Phone | 203-554-7604 |
| Currency | USD |
| Employees | 68 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 23.76 |
| Quick Ratio | 23.76 |
| Cash Ratio | 2.98 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.65 |
| Price / Cash Flow | -35.92 |
| Price / Book | 9.92 |
Price Target and Rating
| Average Stock Price Forecast | $155.50 |
| High Stock Price Forecast | $200.00 |
| Low Stock Price Forecast | $120.00 |
| Forecast Upside/Downside | -43.75% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.31 |
| Trailing P/E Ratio | -36.60 |
| PEG Ratio | -0.45 |
| P/E Growth | -0.45 |
| Net Income | $-105.43M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -25.99% |
| Return on Assets | -23.04% |
Financials Score
| AltmanZ Score | 107.89 |
| Piotroski Score | 1.00 |
| Working Capital | 378.62M |
| Total Assets | 504.48M |
| Ebit | -116.25M |
| Market Cap | 3.21B |
| Total Liabilities | 17.76M |
Poll Results
About Oruka Therapeutics, Inc. (NASDAQ:ORKA) Stock
Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002. The company's main operations are based in Menlo Park, CA. ...
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
2026-06-27 15:28:05
This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.
2026-06-24 17:24:01
Arjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weighted average price of $59.07 per share on May 18, 2026. This sale represented 38.5% of Agarwal's direct holdings, reducing direct ownership from 26,696 to 16,406 shares.
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
2026-06-12 13:01:14
Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2026-06-10 10:56:04
The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million
2026-05-31 10:21:54
This clinical-stage biotech focused on antibody therapies for immunological disorders reported a notable insider sale in its latest filing.
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-28 08:00:00
MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its presentation at the 2026 Jefferies Global Healthcare Conference, taking place in New York, NY from June 2-4, 2026.
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-13 16:03:00
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally
2026-05-13 15:49:47
This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications.
Frequently Asked Questions
-
What is the current Oruka Therapeutics, Inc. (ORKA) stock price?
-
Oruka Therapeutics, Inc.(NASDAQ:ORKA) stock price is $87.47 in the last trading session. During the trading session, ORKA stock reached the peak price of $97.78 while $12.84 was the lowest point it dropped to. The percentage change in ORKA stock occurred in the recent session was 3.44% while the dollar amount for the price change in ORKA stock was $2.91.
-
ORKA's industry and sector of operation?
-
The NASDAQ listed ORKA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ORKA?
-
Christopher Finch | Senior VP and Head of Business Development & Strategy
Laura Sandler | Chief Operating Officer
Joana Goncalves | Chief Medical Officer
Lawrence Otto Klein | President, Chief Executive Officer & Director
Rajiv Panwar | Senior VP and Head of Chemistry, Manufacturing & Controls -
How many employees does ORKA have?
-
Number of ORKA employees currently stands at 68. ORKA operates from 221 Crescent Street Building 23, Suite 105, Menlo Park, CA None, US.
-
Link for ORKA official website?
-
Official Website of ORKA is: http://www.orukatx.com
-
How do I contact ORKA?
-
ORKA could be contacted at phone #203-554-7604 and can also be accessed through its website. ORKA operates from 221 Crescent Street Building 23, Suite 105, Menlo Park, CA None, US.
-
How many shares of ORKA are traded daily?
-
The average number of ORKA shares traded daily for last 3 months was 1.82M.
-
What is the market cap of ORKA currently?
-
The market value of ORKA currently stands at $3.28B with its latest stock price at $87.47